Next Article in Journal
Abstract Book of the SOHO 3rd Italian Conference | 27–30 September 2021
Previous Article in Journal
How I Manage Systemic Light Chain Amyloidosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 13
Issue 3
10.4081/hr.2021.9169
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Apixaban and Eftrenonacog Alfa Treatment in a Patient with Moderate Hemophilia B and Cardiovascular Disease

by
Rita C. Santoro
1,*,
Mariapia Falbo
1 and
Alessandro Ferraro
2
1
Hemostasis and Thrombosis Unit, Azienda Ospedaliera “Pugliese Ciaccio” Viale Pio X, 88100 Catanzaro, Italy
2
Cardiology Unit, Azienda Ospedaliera “Pugliese Ciaccio”, 88100 Catanzaro, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2021, 13(3), 9169; https://doi.org/10.4081/hr.2021.9169
Submission received: 7 April 2021 / Revised: 18 August 2021 / Accepted: 30 August 2021 / Published: 24 September 2021

Abstract

In developed countries, the life expectancy of patients with hemophilia (PwH) is now close to that of the unaffected male population. This means that these patients are at risk of developing age-related comorbidities, including cardiovascular disease. Managing cardiovascular disease in PwH patients can be particularly challenging, due to their high bleeding risk. To our knowledge, this is the first report of a male patient with moderate hemophilia B and hypertensive ischemic heart disease complicated by arrhythmia due to nonvalvular atrial fibrillation, who was treated with apixaban and left atrial appendage closure while receiving concomitant anti-hemorrhagic prophylaxis with eftrenonacog alfa.
Keywords: apixaban; atrial fibrillation; factor IX Fc fusion protein; hemophilia B; cardiovascular surgical procedures apixaban; atrial fibrillation; factor IX Fc fusion protein; hemophilia B; cardiovascular surgical procedures

Share and Cite

MDPI and ACS Style

Santoro, R.C.; Falbo, M.; Ferraro, A. Apixaban and Eftrenonacog Alfa Treatment in a Patient with Moderate Hemophilia B and Cardiovascular Disease. Hematol. Rep. 2021, 13, 9169. https://doi.org/10.4081/hr.2021.9169

AMA Style

Santoro RC, Falbo M, Ferraro A. Apixaban and Eftrenonacog Alfa Treatment in a Patient with Moderate Hemophilia B and Cardiovascular Disease. Hematology Reports. 2021; 13(3):9169. https://doi.org/10.4081/hr.2021.9169

Chicago/Turabian Style

Santoro, Rita C., Mariapia Falbo, and Alessandro Ferraro. 2021. "Apixaban and Eftrenonacog Alfa Treatment in a Patient with Moderate Hemophilia B and Cardiovascular Disease" Hematology Reports 13, no. 3: 9169. https://doi.org/10.4081/hr.2021.9169

APA Style

Santoro, R. C., Falbo, M., & Ferraro, A. (2021). Apixaban and Eftrenonacog Alfa Treatment in a Patient with Moderate Hemophilia B and Cardiovascular Disease. Hematology Reports, 13(3), 9169. https://doi.org/10.4081/hr.2021.9169

Article Metrics

Back to TopTop